Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20080910/NEW068LOGO )
Mr. Sheckler began his career with the Ross Division of AbbottLaboratories, selling nutritional and pharmaceutical products. During his timethere, he served in a variety of sales roles, winning numerous awards. As amarket research analyst, Mr. Sheckler was responsible for the marketassessment and product launch plans for several line extensions.
Advertisement
Mr. Sheckler left Ross in 1999 to join Bespak, Inc., a drug deliverytechnology company, where he held several roles of increasing responsibility.As Head of Marketing for the newly created Nasal Drug Delivery business, hewas instrumental in launching the business stream, assessing and growing newbusiness opportunities in the U.S., and developing and implementing the launchand marketing plans for new products.
Upon leaving Bespak, Mr. Sheckler joined Intranasal Technology, Inc, aKentucky-based nasal drug delivery company as Director of Business Developmentwhere he successfully created and implemented a business development andmarketing communications strategy positioning the company for its entry intothe nasal analgesia market.
Prior to joining SoluBest, Mr. Sheckler served as Vice President ofBusiness Development at Javelin Pharmaceuticals. During his tenure, herealized annual savings of $350M through recognizing and negotiating a newcontract manufacturing agreement and strengthened a successful $32M fundraiserthrough serving an integral role in investor conferences and road shows.
Mr. Sheckler graduated from Indiana University and obtained his MBA fromThe Fuqua School of Business at Duke University in Durham, North Carolina. Hehas been an Editorial Advisor for the journal, "Specialty Pharma," and haschaired and spoken at numerous industry conferences. Mr. Sheckler has authoredseveral articles which have been published in industry magazines.
"SoluBest has successfully advanced its technology in a criticallyimportant area of medicine. This promises to enhance patient outcomes throughinnovative and improved drug delivery. Now, with Michael Sheckler joining ourtalented team, we are confident that his added value will allow us to realizethat promise in short order," said SoluBest Board Chairman Ronnie Hershman,M.D.
"I'm excited to have the opportunity to lead SoluBest to the next level ofgrowth and commercialization. I share the passion of our Board andshareholders to bring our state-of-the-art technology to the pharmaceuticalmarket in order to provide solubility-enhancing formulations for our partners'currently marketed and pipeline molecules," commented Mr. Sheckler.
About SoluBest
SoluBest is a clinical stage company developing proprietarynanoformulation-based improvements of existing compounds and compounds indevelopment.
The company applies its Solumer(TM) technology to poorly soluble orinsoluble drugs which have not achieved their therapeutic potential due todelivery and/or compliance deficiencies.
The Company's proprietary solubilization technology is versatile and iswidely applicable to numerous off-patent (or soon to be off-patent) drugs andnew chemical entities (NCE's).
A significant advantage of the technology stems from its use of readilyavailable equipment for a process consisting of a few simple steps - makingscale-up safe, robust, rapid and inexpensive.
For more information, visit www.solubest.com.
SOURCE SoluBest Ltd.
